Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | TGX-007 + Valacyclovir |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| TGX-007 | TGX007|TGX 007 | TGX-007 comprises an adeno-associated viral vector expressing IL-12 and HSV-TK, which when expressed in the presence of a guanosine analog prodrug can activate the prodrug to produce ganclovir, potentially leading to inhibition of DNA synthesis and antitumor immune activity (NCI Thesaurus). | ||
| Valacyclovir | Valtrex | Acicloftal | Valacyclovir is the prodrug of acyclovir, which is an antiviral agent that functions by inhibiting viral DNA polymerase (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07346144 | Phase Ib/II | TGX-007 + Valacyclovir | Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma (ADePT) | Recruiting | USA | GBR | 0 |